U.S. markets close in 4 hours 7 minutes

Immunotech Biopharm Ltd (6978.HK)

HKSE - HKSE Delayed Price. Currency in HKD
Add to watchlist
15.580-1.420 (-8.35%)
At close: 4:08PM HKT

Immunotech Biopharm Ltd

Guosheng Technology Park
8th Floor, Block 1 No.1 Kangding Street Beijing Eco-Tech Dev Area


Full Time Employees207

Key Executives

NameTitlePayExercisedYear Born
Dr. Yu WangChief Exec. Officer, Exec. Director, Co-Chief Technology OfficerN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.


Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China. Its core product is EAL, a multi-target cellular immunotherapy product that is in Phase II clinical trials for the prevention of postsurgical recurrence of liver cancer. The company is also conducting pre-clinical and clinical trial studies for EAL to treat lung cancer, glioma, gastric cancer, and colorectal cancer. Its products also include CAR-T cell series products for the treatment of hematologic cancer; and TCR-T cell series products for solid tumour treatment. The company was founded in 2006 and is headquartered in Beijing, the People's Republic of China.

Corporate Governance

Immunotech Biopharm Ltd’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.